Prognostic Study of Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease Based on Metabolomics, and Lipidomics (BIPass II)

Prognostic Study of Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease Based on Metabolomics, and Lipidomics

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05550805

Enrollment

5822

Registered

2022-09-22

Start date

2017-11-01

Completion date

2022-03-01

Last updated

2025-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease

Brief summary

To investigate whether there were differences in metabolomics and lipidomics in patients with coronary artery disease who had major adverse cardiovascular events during follow-up compared with those who did not.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Hospitalized patients with the diagnosis of any type of coronary artery disease; 2. Age ≥18 years of age; 3. Patient or guardian provided informed written consent.

Exclusion criteria

1. Prior surgery, trauma or clinically evident coagulopathic bleeding within the previous 2 weeks; 2. Bipass population with missing follow-up records in Qilu Hospital emergency follow-up cohort.

Design outcomes

Primary

Measure	Time frame	Description
major adverse cardiovascular events	20191101-20220701	cardiac death, myocardial infarction, heart failure, stroke

Countries

China

Outcome results